Latest Insider Transactions at Mersana Therapeutics, Inc. (MRSN)
This section provides a real-time view of insider transactions for Mersana Therapeutics, Inc. (MRSN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mersana Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mersana Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 17
2023
|
Tushar Misra SVP, Chief Manuf. Officer |
SELL
Open market or private sale
|
Direct |
1,908
-14.22%
|
$1,908
$1.18 P/Share
|
|
Aug 16
2023
|
Tushar Misra SVP, Chief Manuf. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+31.78%
|
-
|
|
Jul 03
2023
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,217
+16.05%
|
-
|
|
Jul 03
2023
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,079
+1.07%
|
-
|
|
Jun 08
2023
|
Andrew A. F. Hack |
BUY
Grant, award, or other acquisition
|
Direct |
14,467
+50.0%
|
-
|
|
Jun 08
2023
|
Lawrence M Alleva Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,467
+50.0%
|
-
|
|
Jun 08
2023
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,467
+2.53%
|
-
|
|
Jun 08
2023
|
Martin H. Huber Jr. President, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
14,467
+50.0%
|
-
|
|
Jun 08
2023
|
Kristen Hege Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,467
+50.0%
|
-
|
|
Jun 08
2023
|
Allene M. Diaz Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,467
+50.0%
|
-
|
|
Jun 08
2023
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,467
+44.78%
|
-
|
|
Apr 27
2023
|
Alejandra Carvajal SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,944
-16.25%
|
$11,832
$3.89 P/Share
|
|
Apr 26
2023
|
Alejandra Carvajal SVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,250
+35.31%
|
-
|
|
Apr 03
2023
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,866
+0.89%
|
-
|
|
Apr 03
2023
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,375
+50.0%
|
-
|
|
Jan 17
2023
|
Anna Protopapas Director |
SELL
Open market or private sale
|
Direct |
17,346
-26.25%
|
$86,730
$5.74 P/Share
|
|
Jan 17
2023
|
Arvin Yang SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,209
-6.69%
|
$11,045
$5.74 P/Share
|
|
Jan 17
2023
|
Ashish Mandelia VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,575
-20.79%
|
$17,875
$5.74 P/Share
|
|
Jan 17
2023
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
SELL
Open market or private sale
|
Direct |
6,233
-3.34%
|
$31,165
$5.74 P/Share
|
|
Jan 17
2023
|
Tushar Misra SVP, Chief Manuf. Officer |
SELL
Open market or private sale
|
Direct |
458
-7.17%
|
$2,290
$5.74 P/Share
|
|
Jan 17
2023
|
Alejandra Carvajal SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
782
-6.63%
|
$3,910
$5.74 P/Share
|
|
Jan 17
2023
|
Brian De Schuytner SVP, COO & CFO |
SELL
Open market or private sale
|
Direct |
5,131
-13.53%
|
$25,655
$5.74 P/Share
|
|
Jan 15
2023
|
Anna Protopapas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
38,958
+25.83%
|
-
|
|
Jan 15
2023
|
Ashish Mandelia VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,352
+13.13%
|
-
|
|
Jan 15
2023
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,209
+4.0%
|
-
|
|
Jan 15
2023
|
Brian De Schuytner SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,208
+12.5%
|
-
|
|
Jan 14
2023
|
Anna Protopapas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
16,750
+38.18%
|
-
|
|
Jan 14
2023
|
Arvin Yang SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,084
+17.66%
|
-
|
|
Jan 14
2023
|
Ashish Mandelia VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,784
+28.77%
|
-
|
|
Jan 14
2023
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,792
+2.72%
|
-
|
|
Jan 14
2023
|
Tushar Misra SVP, Chief Manuf. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,459
+18.59%
|
-
|
|
Jan 14
2023
|
Alejandra Carvajal SVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+17.48%
|
-
|
|
Jan 14
2023
|
Brian De Schuytner SVP, COO & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+18.41%
|
-
|
|
Dec 14
2022
|
Timothy B Lowinger SVP, Chief Sci.&Tech. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,361
+9.97%
|
$35,361
$1.47 P/Share
|
|
Dec 01
2022
|
Arvin Yang SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,527
-17.56%
|
$33,162
$6.59 P/Share
|
|
Nov 30
2022
|
Arvin Yang SVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+37.02%
|
-
|
|
Aug 17
2022
|
Tushar Misra SVP, Chief Manuf. Officer |
SELL
Open market or private sale
|
Direct |
1,879
-30.06%
|
$13,153
$7.1 P/Share
|
|
Aug 16
2022
|
Tushar Misra SVP, Chief Manuf. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
-
|
|
Jun 02
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
14,760
+0.17%
|
$44,280
$3.2 P/Share
|
|
May 31
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
80,759
+0.93%
|
$242,277
$3.28 P/Share
|
|
May 26
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
75,000
+0.87%
|
$225,000
$3.19 P/Share
|
|
May 25
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
90,155
+1.05%
|
$270,465
$3.17 P/Share
|
|
May 24
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.18%
|
$300,000
$3.29 P/Share
|
|
May 23
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
15,599
+0.19%
|
$46,797
$3.35 P/Share
|
|
May 20
2022
|
Anna Protopapas Director |
BUY
Bona fide gift
|
Indirect |
240,244
+50.0%
|
-
|
|
May 20
2022
|
Anna Protopapas Director |
SELL
Bona fide gift
|
Direct |
240,244
-95.86%
|
-
|
|
May 20
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.19%
|
$300,000
$3.46 P/Share
|
|
May 19
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.21%
|
$300,000
$3.49 P/Share
|
|
May 18
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
211,268
+2.55%
|
$633,804
$3.35 P/Share
|
|
May 17
2022
|
Andrew A. F. Hack |
BUY
Open market or private purchase
|
Indirect |
3,440
+0.04%
|
$10,320
$3.18 P/Share
|